Hepatitis C – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Hepatitis C – Pipeline Review, H2 2019’, provides an overview of the Hepatitis C pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hepatitis C

– The report reviews pipeline therapeutics for Hepatitis C by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hepatitis C therapeutics and enlists all their major and minor projects

– The report assesses Hepatitis C therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hepatitis C

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hepatitis C

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Pharma Ltd

AbbVie Inc

AIMM Therapeutics BV

Akshaya Bio Inc

Alla Chem LLC

Ascletis Pharma Inc

Atea Pharmaceuticals Inc

Beijing Kawin Technology Share-Holding Co Ltd

Beta Pharma Inc

Biotest Pharmaceuticals Corp

Biotron Ltd

Boehringer Ingelheim International GmbH

Bolder Biotechnology Inc

Bristol-Myers Squibb Co

Chia Tai Tianqing Pharmaceutical Group Co Ltd.

Cocrystal Pharma Inc

Combioxin SA

DEKK-TEC Inc

Dongguan HEC TaiGen Biopharmaceuticals Co Ltd

Ena Therapeutics Pty Ltd

Ennaid Therapeutics LLC

F. Hoffmann-La Roche Ltd

FortuneRock (China) Ltd

Galactica Biotech Ltd

GeneCure LLC

Genoscience Pharma

Gilead Sciences Inc

GinkgoPharma Co Ltd

GlaxoSmithKline Plc

HEC Pharm Co Ltd

Hepion Pharmaceuticals

ImmuneMed Inc

ImmunoBiology Ltd

Immunotope Inc

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

iQur Ltd

J2H Biotech

Medivir AB

Merck & Co Inc

MetalloPharm LLC

Microbio Co Ltd

MultiCell Technologies Inc

Nanjing Sanhome Pharmaceutical Co Ltd

Nanogen Biopharmaceutical Co

Novalex Therapeutics Inc

Ono Pharmaceutical Co Ltd

Palisades Therapeutics

PharmaEssentia Corp

Presidio Pharmaceuticals Inc

Profectus BioSciences Inc

Regulus Therapeutics Inc

Riboscience LLC

Rodos BioTarget GmbH

Savoy Pharmaceuticals Inc

Shanghai Newsummit Biopharma Co Ltd

Shanghai Tangrun Pharmaceuticals Co Ltd

Sino Biopharmaceutical Ltd

Sudershan Biotech Ltd

TaiGen Biotechnology Co Ltd

Tetranov International Inc

TGV Laboratories Inc

Therapure Biopharma Inc

THEVAX Genetics Vaccine USA Inc

Toray Industries Inc

Trek Therapeutics PBC

UBI Pharma Inc

Vertex Pharmaceuticals Inc

Virocovax

WhanIn Pharmaceutical Co Ltd

Zylacta Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Hepatitis C Overview 7

Hepatitis C Therapeutics Development 8

Hepatitis C Therapeutics Assessment 27

Hepatitis C Companies Involved in Therapeutics Development 37

Hepatitis C Drug Profiles 62

Hepatitis C Dormant Projects 348

Hepatitis C Discontinued Products 368

Hepatitis C Product Development Milestones 373

Appendix 383

List of Tables

List of Tables

Number of Products under Development for Hepatitis C, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hepatitis C – Pipeline by AB Pharma Ltd, H2 2019

Hepatitis C – Pipeline by AbbVie Inc, H2 2019

Hepatitis C – Pipeline by AIMM Therapeutics BV, H2 2019

Hepatitis C – Pipeline by Akshaya Bio Inc, H2 2019

Hepatitis C – Pipeline by Alla Chem LLC, H2 2019

Hepatitis C – Dormant Projects, H2 2019

Hepatitis C – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Hepatitis C, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports